Cargando…

Circulating long non-coding RNA GAS5 (growth arrest-specific transcript 5) as a complement marker for the detection of malignant mesothelioma using liquid biopsies

BACKGROUND: For the detection of malignant mesothelioma additional markers are needed besides the established panel consisting of calretinin and mesothelin. The aim of this study was the identification and verification of long non-coding RNAs (lncRNAs) as complementing circulating markers. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Weber, Daniel G., Casjens, Swaantje, Brik, Alexander, Raiko, Irina, Lehnert, Martin, Taeger, Dirk, Gleichenhagen, Jan, Kollmeier, Jens, Bauer, Torsten T., Brüning, Thomas, Johnen, Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222324/
https://www.ncbi.nlm.nih.gov/pubmed/32435497
http://dx.doi.org/10.1186/s40364-020-00194-4
_version_ 1783533548508020736
author Weber, Daniel G.
Casjens, Swaantje
Brik, Alexander
Raiko, Irina
Lehnert, Martin
Taeger, Dirk
Gleichenhagen, Jan
Kollmeier, Jens
Bauer, Torsten T.
Brüning, Thomas
Johnen, Georg
author_facet Weber, Daniel G.
Casjens, Swaantje
Brik, Alexander
Raiko, Irina
Lehnert, Martin
Taeger, Dirk
Gleichenhagen, Jan
Kollmeier, Jens
Bauer, Torsten T.
Brüning, Thomas
Johnen, Georg
author_sort Weber, Daniel G.
collection PubMed
description BACKGROUND: For the detection of malignant mesothelioma additional markers are needed besides the established panel consisting of calretinin and mesothelin. The aim of this study was the identification and verification of long non-coding RNAs (lncRNAs) as complementing circulating markers. METHODS: Candidate lncRNAs were identified in silico using previously published RNA expression profiles and verified using quantitative PCR (qPCR) in mesothelioma cell lines as well as human plasma samples from mesothelioma patients and asbestos-exposed controls. RESULTS: GAS5 (growth arrest-specific transcript 5) as a single marker is marked by a low sensitivity of 14%, but the combination of GAS5 with calretinin and mesothelin increased the panel’s sensitivity from 64 to 73% at a predefined specificity of 97%. Circulating GAS5 is not affected by pleurectomy before blood collection, age, or smoking status. CONCLUSIONS: GAS5 is verified as an appropriate circulating marker for the supplement of calretinin and mesothelin to detect malignant mesothelioma. Although the sensitivity of GAS5 is too low for the use as a single marker, the addition of GAS5 as a third marker improves the performance of the established marker panel. The benefit of GAS5 for the detection of malignant mesothelioma at early stages needs to be validated in a prospective study.
format Online
Article
Text
id pubmed-7222324
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72223242020-05-20 Circulating long non-coding RNA GAS5 (growth arrest-specific transcript 5) as a complement marker for the detection of malignant mesothelioma using liquid biopsies Weber, Daniel G. Casjens, Swaantje Brik, Alexander Raiko, Irina Lehnert, Martin Taeger, Dirk Gleichenhagen, Jan Kollmeier, Jens Bauer, Torsten T. Brüning, Thomas Johnen, Georg Biomark Res Research BACKGROUND: For the detection of malignant mesothelioma additional markers are needed besides the established panel consisting of calretinin and mesothelin. The aim of this study was the identification and verification of long non-coding RNAs (lncRNAs) as complementing circulating markers. METHODS: Candidate lncRNAs were identified in silico using previously published RNA expression profiles and verified using quantitative PCR (qPCR) in mesothelioma cell lines as well as human plasma samples from mesothelioma patients and asbestos-exposed controls. RESULTS: GAS5 (growth arrest-specific transcript 5) as a single marker is marked by a low sensitivity of 14%, but the combination of GAS5 with calretinin and mesothelin increased the panel’s sensitivity from 64 to 73% at a predefined specificity of 97%. Circulating GAS5 is not affected by pleurectomy before blood collection, age, or smoking status. CONCLUSIONS: GAS5 is verified as an appropriate circulating marker for the supplement of calretinin and mesothelin to detect malignant mesothelioma. Although the sensitivity of GAS5 is too low for the use as a single marker, the addition of GAS5 as a third marker improves the performance of the established marker panel. The benefit of GAS5 for the detection of malignant mesothelioma at early stages needs to be validated in a prospective study. BioMed Central 2020-05-13 /pmc/articles/PMC7222324/ /pubmed/32435497 http://dx.doi.org/10.1186/s40364-020-00194-4 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Weber, Daniel G.
Casjens, Swaantje
Brik, Alexander
Raiko, Irina
Lehnert, Martin
Taeger, Dirk
Gleichenhagen, Jan
Kollmeier, Jens
Bauer, Torsten T.
Brüning, Thomas
Johnen, Georg
Circulating long non-coding RNA GAS5 (growth arrest-specific transcript 5) as a complement marker for the detection of malignant mesothelioma using liquid biopsies
title Circulating long non-coding RNA GAS5 (growth arrest-specific transcript 5) as a complement marker for the detection of malignant mesothelioma using liquid biopsies
title_full Circulating long non-coding RNA GAS5 (growth arrest-specific transcript 5) as a complement marker for the detection of malignant mesothelioma using liquid biopsies
title_fullStr Circulating long non-coding RNA GAS5 (growth arrest-specific transcript 5) as a complement marker for the detection of malignant mesothelioma using liquid biopsies
title_full_unstemmed Circulating long non-coding RNA GAS5 (growth arrest-specific transcript 5) as a complement marker for the detection of malignant mesothelioma using liquid biopsies
title_short Circulating long non-coding RNA GAS5 (growth arrest-specific transcript 5) as a complement marker for the detection of malignant mesothelioma using liquid biopsies
title_sort circulating long non-coding rna gas5 (growth arrest-specific transcript 5) as a complement marker for the detection of malignant mesothelioma using liquid biopsies
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222324/
https://www.ncbi.nlm.nih.gov/pubmed/32435497
http://dx.doi.org/10.1186/s40364-020-00194-4
work_keys_str_mv AT weberdanielg circulatinglongnoncodingrnagas5growtharrestspecifictranscript5asacomplementmarkerforthedetectionofmalignantmesotheliomausingliquidbiopsies
AT casjensswaantje circulatinglongnoncodingrnagas5growtharrestspecifictranscript5asacomplementmarkerforthedetectionofmalignantmesotheliomausingliquidbiopsies
AT brikalexander circulatinglongnoncodingrnagas5growtharrestspecifictranscript5asacomplementmarkerforthedetectionofmalignantmesotheliomausingliquidbiopsies
AT raikoirina circulatinglongnoncodingrnagas5growtharrestspecifictranscript5asacomplementmarkerforthedetectionofmalignantmesotheliomausingliquidbiopsies
AT lehnertmartin circulatinglongnoncodingrnagas5growtharrestspecifictranscript5asacomplementmarkerforthedetectionofmalignantmesotheliomausingliquidbiopsies
AT taegerdirk circulatinglongnoncodingrnagas5growtharrestspecifictranscript5asacomplementmarkerforthedetectionofmalignantmesotheliomausingliquidbiopsies
AT gleichenhagenjan circulatinglongnoncodingrnagas5growtharrestspecifictranscript5asacomplementmarkerforthedetectionofmalignantmesotheliomausingliquidbiopsies
AT kollmeierjens circulatinglongnoncodingrnagas5growtharrestspecifictranscript5asacomplementmarkerforthedetectionofmalignantmesotheliomausingliquidbiopsies
AT bauertorstent circulatinglongnoncodingrnagas5growtharrestspecifictranscript5asacomplementmarkerforthedetectionofmalignantmesotheliomausingliquidbiopsies
AT bruningthomas circulatinglongnoncodingrnagas5growtharrestspecifictranscript5asacomplementmarkerforthedetectionofmalignantmesotheliomausingliquidbiopsies
AT johnengeorg circulatinglongnoncodingrnagas5growtharrestspecifictranscript5asacomplementmarkerforthedetectionofmalignantmesotheliomausingliquidbiopsies
AT circulatinglongnoncodingrnagas5growtharrestspecifictranscript5asacomplementmarkerforthedetectionofmalignantmesotheliomausingliquidbiopsies